

January 2025 – Elite Impact Formulary Changes

How to Use This Document	This document is intended to summarize changes that will go into effect as of January 2025 or as soon as possible (if specified below). Members with current utilization for any negatively affected medications listed below may be notified of upcoming changes in late 2024 and may not be grandfathered. For any new utilizers as of late 2024, grandfathering may be applied until April 1, 2025.
Formulary Strategy	KPP’s formulary management strategy is a value-based approach to provide guidance to our clients and their members by offering access to the safest, most clinically appropriate and cost-effective medications. This strategy, along with other variables such as market share, pipeline and industry-related cost management tools, helps us to meet the pharmacy benefit management needs of our clients.


Positive Changes

Move to Preferred Status

Drug Class	Drug	Rationale	Effective Date
INFLAMMATORY DISEASE	SIMLANDI	Trade Relations	1/1/2025
INFLAMMATORY DISEASE	TYENNE	Trade Relations	1/1/2025
INFLAMMATORY DISEASE	ZYMFENTRA	Trade Relations	1/1/2025
SEIZURE DISORDER	topiramate ER sprinkle capsule	Lowest Net Cost	1/1/2025

Remove Step Therapy Requirement

Drug Class	Drug	Rationale	Effective Date
BENIGN PROSTATIC HYPERPLASIA (BPH)	tadalafil 2.5mg & 5mg	Lowest Net Cost	1/1/2025
ENDOCRINE DISORDER - FERTILITY	CAVERJECT	Lowest Net Cost	1/1/2025



Negative Changes

Add to Other Programs/Modify Programs

Drug Class	Drug (Alternatives)	Rationale	Effective Date
ANTIEMESIS/ ANTIVERTIGO	dronabinol (dexamethasone, ondansetron, methylprednisolone) <i>Updating Step Therapy to remove aprepitant as a step 1 agent</i>	Lowest Net Cost	1/1/2025
BEHAVIORAL HEALTH – ANTIDEPRESSANTS	ZURZUVAE (Sertraline, Citalopram, Fluoxetine, etc.) <i>Move from Non-Specialty to Specialty</i>	Clinical/Safety Strategy	ASAP
URINARY TRACT - FUNCTIONAL DISORDERS	solifenacin (oxybutynin) <i>Updating Step Therapy to make oxybutynin the only step 1 agent</i>	Lowest Net Cost	1/1/2025
HORMONAL DEFICIENCY	paroxetine 7.5mg (Paroxetine HCl, Paroxetine CR, Paroxetine ER) <i>Updating Step Therapy to require trial of TWO agents</i>	Lowest Net Cost	1/1/2025

Add Step Therapy

Drug Class	Drug (Alternatives)	Rationale	Effective Date
ANTIEMESIS/ ANTIVERTIGO	aprepitant (dexamethasone, ondansetron, methylprednisolone)	Lowest Net Cost	1/1/2025
DERMATOLOGY	flurandrenolide cream (Mometasone or Triamcinolone)	Lowest Net Cost	1/1/2025


Move to Non-Preferred

Drug Class	Drug (Alternatives)	Rationale	Effective Date
SEIZURE DISORDER	QUDEXY XR (topiramate tablets/sprinkle capsules)	Lowest Net Cost	1/1/2025
INFLAMMATORY DISEASE	BERINERT (CINRYZE)	Lowest Net Cost	1/1/2025



Move to Excluded


Drug Class	Drug (Alternatives)	Rationale	Effective Date
INFLAMMATORY DISEASE	ADALIMUMAB-ADAZ & HYRIMOZ (HUMIRA, HADLIMA, SIMLANDI)	Trade Relations	1/1/2025
	ACTEMRA (TYENNE)	Trade Relations	1/1/2025
EYE – GLAUCOMA	brinzolamide (brimonidine, dorzolamide, latanoprost, betaxolol)	Lowest Net Cost	1/1/2025
UPPER GI DISORDERS – ULCER DISEASE	dexlansoprazole (omeprazole, esomeprazole, pantoprazole, lansoprazole)	Lowest Net Cost	1/1/2025
CARDIOVASCULAR DISEASE - HYPERTENSION	ALISKIREN (lisinopril, verapamil, benazepril, losartan, etc.)	Lowest Net Cost	1/1/2025
	TEKTURNA/HCTZ (NED) (lisinopril-HCTZ, losartan-HCTZ, etc.)	Lowest Net Cost	1/1/2025
ENDOCRINE DISORDER - FERTILITY	EDEX (sildenafil, tadalafil)	Lowest Net Cost	1/1/2025
CARDIOVASCULAR DISEASE - MISCELLANEOUS AGENTS	amlodipine-atorvastatin & amlodipine-valsartan & amlodipine-valsartan-HCTZ (NED) (separate products)	Lowest Net Cost	1/1/2025
ALLERGY	azelastine-fluticasone nasal spray (NED) (separate products)	Lowest Net Cost	1/1/2025
PAIN MANAGEMENT – ANALGESICS	butalbital-acetaminophen 50mg-300mg (NED) (butalbital-acetaminophen 50mg-325mg)	Lowest Net Cost	1/1/2025
	butalbital-acetaminophen-caffeine-codeine 50-300-30 (NED) (butalbital-acetaminophen-caffeine-codeine 50-325-30)	Lowest Net Cost	1/1/2025
ASTHMA AND COPD	ARCAPTA (STRIVERDI, formoterol)	Lowest Net Cost	1/1/2025
	UTIBRON (ANORO, STIOLTO)	Lowest Net Cost	1/1/2025
BEHAVIORAL HEALTH – ANTIDEPRESSANTS	DESVENLAFAXINE ER 100MG (NED) (venlafaxine, duloxetine, or desvenlafaxine succinate ER)	Lowest Net Cost	1/1/2025
URINARY TRACT - FUNCTIONAL DISORDERS	dutasteride-tamsulosin (NED) (finasteride, alfuzosin, doxazosin, prazosin, silodosin, tamsulosin, or terazosin)	Lowest Net Cost	1/1/2025
URINARY TRACT - FUNCTIONAL DISORDERS	ENABLEX (generic darifenacin)	Lowest Net Cost	1/1/2025
BEHAVIORAL HEALTH – OTHER	EQUETRO CAPSULES (carbamazepine tablets)	Lowest Net Cost	1/1/2025



Kroger
Prescription
Plans

1014 Vine Street, Cincinnati, OH 45202
Phone 800.917.4926 • Fax 866.762.1014
rxplans@kroger.com

Drug Class	Drug (Alternatives)	Rationale	Effective Date
BEHAVIORAL HEALTH – OTHER	clozapine ODT 150mg and 200mg (NED) (clozapine ODT 100mg and 25mg)	Lowest Net Cost	1/1/2025
CARDIOVASCULAR DISEASE - HYPERTENSION	CARDURA XL (generic doxazosin, alfuzosin, prazosin, or tamsulosin)	Lowest Net Cost	1/1/2025
DERMATOLOGY - ANTIINFLAMMATORY	NEO-SYNALAR CREAM (bacitracin, fluocinolone)	Lowest Net Cost	1/1/2025
INFECTIOUS DISEASE – BACTERIAL	CIPRO 5% SUSP (generic ciprofloxacin 5% susp)	Lowest Net Cost	1/1/2025
DIABETES	AVANDIA (pioglitazone, metformin, sulfonylureas, etc.)	Lowest Net Cost	1/1/2025
	BAQSIMI (glucagon emergency kit, GVOKE, ZEGALOGUE)	Lowest Net Cost	1/1/2025
	INSULIN DEGLUDEC (insulin glargine-YFGN, SEMGLEE-YFGN, TRESIBA)	Lowest Net Cost	1/1/2025
OPHTHALMIC NSAID	BROMSITE (bromfenac sodium 0.09%)	Lowest Net Cost	1/1/2025
ENDOCRINE DISORDER – OTHER	FORTEO (TYMLOS, teriparatide)	Lowest Net Cost	1/1/2025
ENDOCRINE DISORDER – FERTILITY	MUSE (CAVERJECT, sildenafil, tadalafil)	Lowest Net Cost	1/1/2025



Kroger
Prescription
Plans

1014 Vine Street, Cincinnati, OH 45202
Phone 800.917.4926 • Fax 866.762.1014
rxplans@kroger.com

RATIONALE OF CHANGES

Trade Relations Strategy

Approach based on a financial review to deliver low net cost opportunities through pharmaceutical manufacture agreement strategies while taking into consideration the expected market share shift, future pipeline products, member impact and plan impact.

Low Net Cost Strategy

Delivering cost-efficient and clinically appropriate formulary content to meet the pharmacy benefit management needs of clients; including appropriate development of preferred drug lists with consideration of low net cost strategies that includes MAC lists, non-pharmaceutical manufacture agreement strategies, and other cost management tools.

Clinical/Safety Strategy

Delivering cost-efficient and clinically appropriate formulary content to promote member safety and savings through the evaluation of scientific evidence, standards of practice, peer-reviewed medical literature, clinical practice guidelines, and guidance from the U.S. Food and Drug Administration (FDA)/Center for Disease Control (CDC).

Regulatory Update

Formulary/utilization management changes to comply with federal and/or state statutes, regulations, rules and policy requirements that pertain to the administration of the pharmacy benefit.